Figure 11. K‐M analysis of recurrence and metastasis using a Mito‐Signature in a larger group of all ER(+) breast cancer patients, independently of treatment. Patients with high‐expression levels of the Mito‐Signature showed near 2‐fold increases in recurrence (N = 3,082; p < 1e‐16) and distant metastasis (N = 1,395; p = 1.1e‐07).